Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin

a phase II randomized trial

Scott M. Lippman, John F. Kassler, Muhyi Al-Sarraf, David S Alberts, Loretta M. Itri, Douglas Mattox, Daniel D. Von Hoff, Lois J Loescher, Frank L. Meyskens

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Retinoids, the analogs of vitamin A, are active in vitro and in vivo against squamous cell carcinoma in animals and against certain epithelial precancers and cancers in humans. These data led us to design a prospective, multi-institutional, randomized phase II trial of isotretinoin in advanced head and neck squamous cell carcinoma. We randomly assigned 40 patients to receive isotretinoin or methotrexate, the best-studied and most active single agent for this disease. Overall, the study patients had extremely poor prognoses, i.e., low performance statuses and recurring disease after surgery and/or irradiation. Three objective responses (16%), including one complete response, occurred in the 19 evaluable isotretinoin-treated patients. Only one minor response (5%) occurred in the methotrexate-treated group. Toxicity occurred with both drugs, but was manageable and never life threatening in the retinoid group. These results and the established activity of retinoids in oral leukoplakia (a precursor of head and neck cancer) indicate the need for further study of this class of drugs in head and neck cancer.

Original languageEnglish (US)
Pages (from-to)51-56
Number of pages6
JournalInvestigational New Drugs
Volume6
Issue number1
DOIs
StatePublished - Apr 1988

Fingerprint

Isotretinoin
Retinoids
Head and Neck Neoplasms
Methotrexate
Oral Leukoplakia
Vitamin A
Pharmaceutical Preparations
Squamous Cell Carcinoma
Therapeutics
Carcinoma, squamous cell of head and neck
Neoplasms

Keywords

  • head and neck cancer
  • retinoids
  • squamous cell carcinoma

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin : a phase II randomized trial. / Lippman, Scott M.; Kassler, John F.; Al-Sarraf, Muhyi; Alberts, David S; Itri, Loretta M.; Mattox, Douglas; Von Hoff, Daniel D.; Loescher, Lois J; Meyskens, Frank L.

In: Investigational New Drugs, Vol. 6, No. 1, 04.1988, p. 51-56.

Research output: Contribution to journalArticle

Lippman, Scott M. ; Kassler, John F. ; Al-Sarraf, Muhyi ; Alberts, David S ; Itri, Loretta M. ; Mattox, Douglas ; Von Hoff, Daniel D. ; Loescher, Lois J ; Meyskens, Frank L. / Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin : a phase II randomized trial. In: Investigational New Drugs. 1988 ; Vol. 6, No. 1. pp. 51-56.
@article{c8732e72ee344d45998a383d00c7ae25,
title = "Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: a phase II randomized trial",
abstract = "Retinoids, the analogs of vitamin A, are active in vitro and in vivo against squamous cell carcinoma in animals and against certain epithelial precancers and cancers in humans. These data led us to design a prospective, multi-institutional, randomized phase II trial of isotretinoin in advanced head and neck squamous cell carcinoma. We randomly assigned 40 patients to receive isotretinoin or methotrexate, the best-studied and most active single agent for this disease. Overall, the study patients had extremely poor prognoses, i.e., low performance statuses and recurring disease after surgery and/or irradiation. Three objective responses (16{\%}), including one complete response, occurred in the 19 evaluable isotretinoin-treated patients. Only one minor response (5{\%}) occurred in the methotrexate-treated group. Toxicity occurred with both drugs, but was manageable and never life threatening in the retinoid group. These results and the established activity of retinoids in oral leukoplakia (a precursor of head and neck cancer) indicate the need for further study of this class of drugs in head and neck cancer.",
keywords = "head and neck cancer, retinoids, squamous cell carcinoma",
author = "Lippman, {Scott M.} and Kassler, {John F.} and Muhyi Al-Sarraf and Alberts, {David S} and Itri, {Loretta M.} and Douglas Mattox and {Von Hoff}, {Daniel D.} and Loescher, {Lois J} and Meyskens, {Frank L.}",
year = "1988",
month = "4",
doi = "10.1007/BF00170781",
language = "English (US)",
volume = "6",
pages = "51--56",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin

T2 - a phase II randomized trial

AU - Lippman, Scott M.

AU - Kassler, John F.

AU - Al-Sarraf, Muhyi

AU - Alberts, David S

AU - Itri, Loretta M.

AU - Mattox, Douglas

AU - Von Hoff, Daniel D.

AU - Loescher, Lois J

AU - Meyskens, Frank L.

PY - 1988/4

Y1 - 1988/4

N2 - Retinoids, the analogs of vitamin A, are active in vitro and in vivo against squamous cell carcinoma in animals and against certain epithelial precancers and cancers in humans. These data led us to design a prospective, multi-institutional, randomized phase II trial of isotretinoin in advanced head and neck squamous cell carcinoma. We randomly assigned 40 patients to receive isotretinoin or methotrexate, the best-studied and most active single agent for this disease. Overall, the study patients had extremely poor prognoses, i.e., low performance statuses and recurring disease after surgery and/or irradiation. Three objective responses (16%), including one complete response, occurred in the 19 evaluable isotretinoin-treated patients. Only one minor response (5%) occurred in the methotrexate-treated group. Toxicity occurred with both drugs, but was manageable and never life threatening in the retinoid group. These results and the established activity of retinoids in oral leukoplakia (a precursor of head and neck cancer) indicate the need for further study of this class of drugs in head and neck cancer.

AB - Retinoids, the analogs of vitamin A, are active in vitro and in vivo against squamous cell carcinoma in animals and against certain epithelial precancers and cancers in humans. These data led us to design a prospective, multi-institutional, randomized phase II trial of isotretinoin in advanced head and neck squamous cell carcinoma. We randomly assigned 40 patients to receive isotretinoin or methotrexate, the best-studied and most active single agent for this disease. Overall, the study patients had extremely poor prognoses, i.e., low performance statuses and recurring disease after surgery and/or irradiation. Three objective responses (16%), including one complete response, occurred in the 19 evaluable isotretinoin-treated patients. Only one minor response (5%) occurred in the methotrexate-treated group. Toxicity occurred with both drugs, but was manageable and never life threatening in the retinoid group. These results and the established activity of retinoids in oral leukoplakia (a precursor of head and neck cancer) indicate the need for further study of this class of drugs in head and neck cancer.

KW - head and neck cancer

KW - retinoids

KW - squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0023910012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023910012&partnerID=8YFLogxK

U2 - 10.1007/BF00170781

DO - 10.1007/BF00170781

M3 - Article

VL - 6

SP - 51

EP - 56

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -